CBAK Energy Technology is not a broadly followed name. After reviewing available brokerage research, only one current, attributable price target could be verified: $1.50 per share, from Zacks Small-Cap Research. A second sell-side name, Roth Capital Partners, has historically covered the company, but no current, dated target from that firm could be confirmed. Because a single target cannot form a meaningful average, the $1.50 figure is treated here as the realistic objective being discussed publicly rather than an "analyst consensus."
Notably, that target was lowered 25% — from $2.00 to $1.50 — following third-quarter 2025 results, even as the covering analyst raised revenue and EPS (earnings per share) estimates. The analyst now models roughly $343 million in 2026 revenue and a return to profitability of about $0.10 per share. This mix — better estimates paired with a lower valuation target — signals caution about margins, capacity ramp timing, and headline risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CBAK Energy Technology, Inc. (Nasdaq: CBAT) is a Dalian, China-based manufacturer of lithium-ion and sodium-ion rechargeable batteries, operating through its CBAK battery segment and its Hitrans battery-materials segment. It is a microcap that has traded in a wide range — roughly $0.46 to $1.55 over the past year — and has recently changed hands near $0.85.
At that level, a move to $1.50 implies upside of approximately 75%, which is a very large advance. The path would likely require several things to occur together: sustained revenue growth as new production lines ramp, a credible return to positive earnings, and a durable share-price recovery back above the $1.00 Nasdaq compliance threshold. Management guided that consolidated sales should hit a record in 2026 as new capacity comes online, and the single covering analyst forecasts a swing from a loss to roughly $0.10 per share in profit. Still, translating growth into share-price appreciation of this magnitude is not a given.
Several verified factors could help. Revenue has been expanding sharply — fourth-quarter 2025 consolidated revenue rose about 132% year over year to $58.8 million — and third-quarter results exceeded expectations. The company is investing heavily in new capacity, including a 2.3 GWh (gigawatt-hour) Dalian cell line and a large-format sodium-ion project in Nanjing, and it reported a strong cash position. Sodium-ion technology and energy-storage demand offer longer-term growth avenues, and the analyst expects the business to return to profitability in 2026. A recovery above $1.00, combined with improving margins and any new commercial orders, could re-anchor investor sentiment toward the higher $1.50 objective. From what I see, this capacity expansion stands out as a key catalyst.
The obstacles are substantial. The company reported a net loss on a trailing twelve-month basis, and gross margin compressed to 7.3% in the fourth quarter of 2025, down from 13.1% a year earlier, reflecting unit costs and fixed-cost absorption during capacity ramp-ups. In April 2026 the company disclosed a Nasdaq notice that its shares had fallen below the $1.00 minimum bid price, a compliance risk that can weigh on a microcap. As a China-headquartered exporter, CBAT also faces tariff and regulatory exposure, including the phase-out of export tax rebates, which it is addressing through a Malaysia localization plan. Finally, thin analyst coverage and a history of sharp price swings add to execution and sentiment risk.
The $1.00 level is the most consequential marker: it is both a psychological round number and the Nasdaq minimum-bid compliance threshold. The stock has been trading below its longer-term moving averages, and the 52-week low near $0.46 stands as a key support zone, while the prior peak near $1.55 marks the clearest overhead resistance. For the $1.50 target to become relevant, the shares would first need to reclaim and hold above $1.00 and then push through the $1.20-to-$1.24 area that capped earlier rallies. I’m watching this closely as technical confirmation could shift the setup.
A single price target typically reflects a roughly 12-month research horizon, though the actual period can vary. Because only one analyst is active here, there is no range of horizons to compare. Investors should watch quarterly results and gross-margin trends, the ramp of the Dalian and Nanjing capacity, any return to positive EPS, new battery or materials orders, and progress on Malaysia localization. Equally important are any Nasdaq compliance updates and the direction of U.S.-China trade policy, which can move sentiment quickly for a sub-$1 exporter.
In my research process, I find Tickeron's AI Daily Buy/Sell Signals helpful for gaining a more systematic view. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical behavior, and AI-driven analysis. It can assist traders in spotting opportunities and tracking shifts more efficiently than manual methods alone, though it serves best as a complement to independent research.
Can CBAK Energy Technology reach $1.50? The target is real but rests on a single analyst, and it was already cut 25% even as estimates improved. From roughly $0.85, the required move of about 75% is very large, and the stock carries meaningful execution, margin, and Nasdaq-compliance risks. The supportive case — accelerating revenue, new capacity, sodium-ion optionality, and a projected return to profit — is genuine, but it must overcome persistent losses and a sub-$1 share price. The $1.50 figure is best understood as an optimistic, thin-coverage objective rather than a forecast, and investors should monitor margins, earnings, compliance news, and trade policy before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Stochastic Oscillator for CBAT moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 49 similar instances where the indicator exited the overbought zone. In 41 of the 49 cases the stock moved lower. This puts the odds of a downward move at 84%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CBAT as a result. In 82 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
CBAT moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CBAT crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for CBAT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CBAT's RSI Oscillator exited the oversold zone, 29 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for CBAT just turned positive on October 30, 2026. Looking at past instances where CBAT's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Following a +3.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBAT advanced for three days, in 180 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.881) is normal, around the industry mean (2.765). P/E Ratio (-5.806) is within average values for comparable stocks, (13.467). Projected Growth (PEG Ratio) (0.050) is also within normal values, averaging (2.910). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (0.395) is also within normal values, averaging (9.055).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. CBAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of lithium batteries and related renewable energy products
Industry ElectricalProducts